Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial diseases that Pleiogenix is targeting are acute alcoholic hepatitis (AAH), COVID-19, and non-alcoholic steatohepatitis (NASH) / Fibrosis, with additional diseases to follow. AAH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. NASH is a severe form of the chronic liver disease, non-alcoholic fatty liver disease (NAFLD). The AAH market is estimated to be $575 million by 2023, while the NASH market is estimated to be $35-40 billion by 2025. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; there have been over 25 million cases resulting in ~850,000 deaths (globally). There are no approved therapeutics that prevent or treat AAH, NASH, or COVID-19. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic and metabolic clinical benefits. In patients suffering from AAH, NASH, and COVID-19, inflammation is severely increased, and adiponectin is reduced in patients with NASH. Increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical for AAH, NASH / fibrosis, and/or COVID-19.